Last updated: February 21, 2026
What does AU2024205278 cover regarding drug inventions?
The patent AU2024205278, titled "Pharmaceutical compounds and their use", was filed on August 30, 2024. It is assigned to a pharmaceutical innovator focused on small-molecule therapeutics targeting specific pathways.
Patent Scope Description
The patent claims cover a new class of heterocyclic compounds designed as modulators of a specified biological pathway. The claims include:
- The chemical structure of the compounds, represented by a core scaffold with variable substituents.
- Methods of synthesizing the compounds.
- Use of the compounds in treating specific indications, notably inflammation and autoimmune diseases.
- Pharmaceutical compositions containing the compounds.
- Methods of administering effective doses of these compounds.
Key Claim Features
- Core structure: A heterocyclic ring system with specific substituents defined by Markush groups.
- Substituents’ scope: Variations include alkyl, aryl, halogen, and heteroaryl groups, with a total of 20 possible substitutions described.
- Use claims: Encompass methods of prevention and treatment in mammals, including humans.
- Method of synthesis: Details cover a multi-step synthetic route with defined reaction conditions.
Claim Type Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent chemical claims |
3 |
Cover the core compounds and specific variants |
| Independent method claims |
2 |
Cover synthesis and therapeutic use |
| Dependent claims |
10 |
Narrow variations on core structures and methods |
The broadest claims cover any heterocyclic compound with the specified core scaffold and certain substituents, potentially claiming extensive chemical space.
Patent Landscape Context for Similar Pharmacological Area
Patent Filings in Related Space
- Global filings: Multiple filings in WIPO (PCT) applications, targeting similar compounds for autoimmune treatments. The earliest filed around 2019.
- Australia filings: AU2024205278 is part of a broader IP strategy, with prior filings and grants in key jurisdictions such as the US, Europe, and China.
- Patent families: The applicant maintains a patent family with intermediate-phase patents protecting synthesis routes and specific therapeutic claims.
Competitor Patent Activity
- Several third-party patents exist covering heterocyclic compounds with related structures, particularly in the US and Europe.
- Competitor patents mostly focus on analogues with specific substitutions claiming improved potency or reduced side effects.
- Recent filings (2021-2023) target mechanisms of action similar to those claimed here, posing potential infringement considerations.
Patentability and Freedom-to-Operate (FTO) Considerations
- The novelty of the compounds hinges on specific substitution patterns not previously disclosed.
- Novelty is supported by the unique combination of certain heteroaryl substituents and synthetic methods.
- The scope of the claims appears broad but could be vulnerable to prior art patents citing similar core structures, especially in European patent EP300XXXX.
Patent Term and Enforcement Status
- Patent term: Expected expiry 20 years from the filing date, i.e., August 30, 2044, subject to potential extension.
- Enforcement: No evidence of litigation or enforcement activities in Australia or other territories as of now.
- Commercial prospects: Pending regulatory approval could influence patent enforcement and licensing strategies.
Key Takeaways
- AU2024205278 claims a broad class of heterocyclic compounds for autoimmune and inflammatory indications.
- The patent’s strength relies on the novelty of chemical substitutions and specific synthesis methods.
- The landscape includes multiple patents, with some overlapping claims, particularly in the US and Europe.
- Patent validity could depend on prior art search results, especially for compounds with similar core scaffolds.
- The patent provides a robust foundation for market exclusivity, assuming successful development and regulatory approval.
FAQs
1. Can the broad chemical claims be challenged for obviousness?
Yes. Prior art compounds with similar heterocyclic cores and substituents are available, which could render some claims obvious.
2. Does the patent cover all possible derivatives of the core structure?
No. It claims specific substitutions, which may limit scope but also provide a narrower, more defensible position.
3. Will existing patents in other jurisdictions impact AU2024205278's enforceability in Australia?
Yes. Australian patents are assessed independently; however, overlapping claims may pose FTO risks and potential infringement issues.
4. How does this patent compare to similar compounds in the patent landscape?
It claims a broader set of substitutions and synthesis methods, potentially giving it a competitive advantage if these claims are upheld.
5. What strategic considerations should a licensee evaluate?
Licensing negotiations should focus on the scope of claims, patent expiry dates, and potential freedom-to-operate issues given existing patents.
Citations
[1] World Intellectual Property Organization. (2023). International Patent Applications. Retrieved from https://www.wipo.int/pct/en/
[2] Australian Patent Office. (2024). Patent AU2024205278 Examination Report and Status. Retrieved from https://data.ipaustralia.gov.au/
[3] European Patent Office. (2022). Patent Search Database. Retrieved from https://espacenet.com/
[4] U.S. Patent and Trademark Office. (2023). Patent Search. Retrieved from https://patft.uspto.gov/
